{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for beta root_polymer_monomers_monomerSubstance_refPname in Monomer Substance Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
Sonifilan by Kaken Pharmaceutical
Source URL:
First approved in 2023
Source:
M016
Source URL:
Class:
POLYMER
Targets:
Conditions:
Sizofiran (Schizophyllan, SPG, Sonifilan, Sizofilan) is a soluble beta-D-glucan produced by the Basidiomycetes fungus, Schizophyllum commune Fries, with potential immunomodulating and antitumor activities. Although sizofiran’s exact mechanism of action has yet to be fully elucidated, this agent appears to stimulate the immune system by increasing cytokine production, activating macrophages and Langerhans cells and enhancing the activity of polymorphonuclear leukocytes (PML) and natural killer (NK) cells. Sizofiran was found rather ineffective against gastric cancer, but extended survival time in patients with head and neck cancer. In cervical cancer, Sizofiran prolonged survival and time to recurrence for stage II cases but not stage III, and showed added effectiveness when injected directly into the tumor mass. Sonifilan is used as a biological response modifier (BRM) with radiation therapy for cancer treatment in Japan. It was launched for cervical cancer in South Korea in 1998.
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2022)
Source URL:
First approved in 2022
Source:
M020
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M020
(2022)
Source URL:
First approved in 2022
Source:
M020
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M020
(2022)
Source URL:
First approved in 2022
Source:
M020
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M020
(2022)
Source URL:
First approved in 2022
Source:
M020
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NCT01944631: Phase 4 Interventional Completed Common Cold
(2013)
Source URL:
First approved in 2021
Source:
NDA203697
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M021
(2021)
Source URL:
First approved in 2021
Source:
M021
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA205882
(2021)
Source URL:
First approved in 2021
Source:
ANDA205882
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA210602
(2021)
Source URL:
First approved in 2021
Source:
ANDA210602
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M020
(2020)
Source URL:
First approved in 2020
Source:
M020
Source URL:
Class:
POLYMER
